menu
    • menu
    [{"orgOrder":0,"company":"CoImmune","sponsor":"FIDIM Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Series A Financing","leadProduct":"CMN-001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"CoImmune","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"CoImmune \/ FIDIM Group","highestDevelopmentStatusID":"8","companyTruncated":"CoImmune \/ FIDIM Group"},{"orgOrder":0,"company":"CoImmune","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"ITI-1020","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"CoImmune","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CoImmune \/ Immunomic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CoImmune \/ Immunomic Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by CoImmune

    Menu

    CoImmune

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CoImmune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            CoImmune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ITI-1020

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Immunomic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Immunomic Therapeutics and CoImmune Therapeutics Enter into Partnership to Manufacture ITI-1020

                            Details : ITI will employ CoImmune’s process for manufacturing and cGMP work for the advancement of ITI-1020, ITI’s autologous dendritic cell (DC) investigational vaccine loading with mRNA encoding LAMP: pp65 for the treatment of newly diagnosed glioblastoma (...

                            Brand Name : ITI-1020

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 19, 2020

                            Lead Product(s) : ITI-1020

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Immunomic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CoImmune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            CoImmune

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMN-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : FIDIM Group

                            Deal Size : $45.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            CoImmune Announces Closing of $45 Million Series A Financing

                            Details : CoImmune will use the proceeds from the financing to fund its ongoing Phase 2b trial for lead asset, CMN-001, in advanced renal cell carcinoma and multiple Phase 1-2a trials with its newly acquired technology, CAR-CIK, in five leukemia and lymphoma setti...

                            Brand Name : CMN-001

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 10, 2020

                            Lead Product(s) : CMN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : FIDIM Group

                            Deal Size : $45.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth